Compare · EW vs EYES
EW vs EYES
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Second Sight Medical Products Inc. (EYES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and EYES operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $47.58B, about 914.6x EYES ($52.0M).
- Over the past year, EW is up 5.3% and EYES is down 1.6% - EW leads by 6.9 points.
- EW has hit the wire 8 times in the past 4 weeks while EYES has been quiet.
- EW has more recent analyst coverage (25 ratings vs 0 for EYES).
- Company
- Edwards Lifesciences Corporation
- Second Sight Medical Products Inc.
- Price
- $82.65-1.31%
- $26.89+4.43%
- Market cap
- $47.58B
- $52.0M
- 1M return
- -7.80%
- +5.70%
- 1Y return
- +5.33%
- -1.61%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Second Sight Medical Products Inc.
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
Latest EW
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
Latest EYES
- SEC Form 4 filed by Mendelsohn Adam
- SEC Form 4 filed by Makes Brigid
- SEC Form 4 filed by Dwyer Donald
- SEC Form 4 filed by Porter Lisa Ellen
- SEC Form 4 filed by Le Truc
- Second Sight Medical Products Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Second Sight Medical Products Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Second Sight Medical Products Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 4: Dwyer Donald bought $14,500 worth of shares (10,000 units at $1.45)
- SEC Form 10-Q filed by Second Sight Medical Products Inc.